novo nordisk septerna - Search News

Order byBest matchMost fresh

News

Novo Nordisk Inks A Major Obesity Deal

Novo Nordisk strikes $2.2 billion deal with Septerna to develop new obesity treatments

Novo Nordisk has struck a collaboration and licensing deal with U.S. biotech Septerna to develop oral small molecule medicines for obesity, type 2 diabetes and other cardio-metabolic diseases that could be worth up to $2.

Continue reading

· 13h · on MSN

· 13h · on MSN

Novo Nordisk and Septerna Strike $2.2 Billion Deal to Develop Obesity Pills

Novo Nordisk taps Septerna in $2.2bn deal for oral obesity therapies

Novo Nordisk strikes deal with Septerna to develop obesity pills

Novo Nordisk is partnering with the biotech Septerna to develop oral obesity drugs, as it aims for more convenient weight ...

pharmaphorum11h

Novo makes fresh obesity play with $2.2bn Septerna deal

It seems Novo Nordisk is leaving no stone unturned as it builds a pipeline of drug candidates for obesity and cardiometabolic ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results